CSL Behring is a specialty biotherapeutics company built on more than a century of service to people with serious medical conditions around the world. Biotherapies differ from conventional chemical-based pharmaceuticals in that they derive from human blood plasma or are manufactured using recombinant technologies. CSL Behring is proud to serve communities of people who have von Willebrand disease (VWD), hemophilia, primary immunodeficiency (PID), hereditary angioedema (HAE), fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and other rare diseases. We also manufacture biotherapies to prevent hemolytic disease of the newborn, and prevent or stop bleeding in emergencies or planned surgery.
Achieving better health
CSL Behring's R&D efforts have resulted in a wide range of products that have had a lasting impact on human health around the world.
Making a difference with one treatment at a time
We bring to market treatments for rare diseases that might not have been produced otherwise
Our commitment and delivering our promise
We are committed to delivering value through fulfilling unmet needs and enhancing patient experience. Our promise is to protect the health and well-being of people with life-threatening medical conditions.
Report an undesirable effect
If you encounter any side effect(s) to a CSL Behring product, we encourage you to talk to your doctor, pharmacist, or nurse.
CSL Behring collects information about undesirable effects in order to monitor product safety and investigate, evaluate and report undesirable effects to appropriate regulatory bodies. In the United States, patients experiencing negative side effects of prescription drugs are encouraged to report them at http://www.fda.gov/medwatch, or by calling 1-800-FDA-1088.